Low long-term efficacy and tolerability of add-on rufinamide in patients with Dravet syndrome

A. Mueller, R. Boor, G. Coppola, P. Striano, M. Dahlin, C. von Stuelpnagel, J. Lotte, M. Staudt, G. Kluger

Research output: Contribution to journalArticle

Abstract

In this retrospective European multicenter study we evaluated the efficacy and tolerability of rufinamide in patients with Dravet syndrome and refractory seizures. Twenty patients were included; in 16 patients a SCN1A mutation was detected. The responder rate after 6. months was 20%, and after 34. months, 5%. The retention rate was 45% after 6. months and 5% after 34. months. Rufinamide treatment was stopped because of aggravation of seizures (30%), no effect (45%), and side effects (10%). The efficacy and long-term retention rate were low in our patients with Dravet syndrome and refractory seizures, far lower than in patients with Lennox-Gastaut syndrome; one-third of our patients experienced seizure aggravation. Therefore, rufinamide does not seem to be a suitable option for long-term treatment in patients with Dravet syndrome.

Original languageEnglish
Pages (from-to)282-284
Number of pages3
JournalEpilepsy and Behavior
Volume21
Issue number3
DOIs
Publication statusPublished - Jul 2011

    Fingerprint

Keywords

  • Dravet syndrome
  • Refractory seizures
  • Rufinamide
  • SCN1A mutation

ASJC Scopus subject areas

  • Clinical Neurology
  • Behavioral Neuroscience
  • Neurology

Cite this

Mueller, A., Boor, R., Coppola, G., Striano, P., Dahlin, M., von Stuelpnagel, C., Lotte, J., Staudt, M., & Kluger, G. (2011). Low long-term efficacy and tolerability of add-on rufinamide in patients with Dravet syndrome. Epilepsy and Behavior, 21(3), 282-284. https://doi.org/10.1016/j.yebeh.2011.04.057